1. Home
  2. HUDI vs APRE Comparison

HUDI vs APRE Comparison

Compare HUDI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huadi International Group Co. Ltd.

HUDI

Huadi International Group Co. Ltd.

HOLD

Current Price

$0.95

Market Cap

11.5M

Sector

Industrials

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.81

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUDI
APRE
Founded
1998
2006
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
11.5M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
HUDI
APRE
Price
$0.95
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
836.2K
44.9K
Earning Date
01-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.55
52 Week High
$5.46
$1.69

Technical Indicators

Market Signals
Indicator
HUDI
APRE
Relative Strength Index (RSI) 56.30 68.82
Support Level $0.90 $0.77
Resistance Level $1.33 $0.81
Average True Range (ATR) 0.10 0.06
MACD 0.02 0.01
Stochastic Oscillator 58.95 80.00

Price Performance

Historical Comparison
HUDI
APRE

About HUDI Huadi International Group Co. Ltd.

Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: